Thyrocare Technologies (539871) Aktienübersicht
Thyrocare Technologies Limited bietet Patienten, Labors und Krankenhäusern in Indien diagnostische Testdienstleistungen an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 4/6 |
539871 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Thyrocare Technologies Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹579.15 |
| 52-Wochen-Hoch | ₹617.30 |
| 52-Wochen-Tief | ₹342.55 |
| Beta | 0.46 |
| 1 Monat Veränderung | 4.00% |
| 3 Monate Veränderung | 44.59% |
| 1 Jahr Veränderung | 31.30% |
| 3 Jahre Veränderung | 203.43% |
| 5 Jahre Veränderung | 28.66% |
| Veränderung seit IPO | 181.14% |
Aktuelle Nachrichten und Updates
Recent updates
Narrative-Update • Jun 19
539871: Expanded Healthcare Objects Clause And New Auditors Will Support Bullish View
Analysts have nudged their fair value estimate for Thyrocare Technologies slightly higher, from ₹600 to ₹603, reflecting updated assumptions around long term profit margins and future P/E expectations. What’s in the News for Thyrocare Technologies A board meeting is scheduled for May 07, 2026 to review and approve the audited standalone and consolidated financial results for the year ended March 31, 2026, and to consider several governance and audit related items (source: Key Developments).Narrative-Update • Jun 04
539871: Expanded Healthcare Objects Clause Will Support Bullish Medium Term View
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹600, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. This indicates that the latest review did not alter their fundamental valuation framework for the stock.Narrative-Update • May 18
539871: Expanded Healthcare Mandate Will Support Bullish Medium Term View
Analysts have lifted their price target on Thyrocare Technologies from ₹571.67 to ₹600.00, and point to updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple as key drivers of the change. What's in the News The Board has approved changes to the Memorandum of Association to align it with the Companies Act, 2013, including updated references and clauses linked to current regulations (Key Developments).Narrative-Update • Apr 28
539871: Stable Return Assumptions Will Support Bullish Medium Term View
Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.Narrative-Update • Apr 09
539871: Stable Assumptions And Upcoming Results Will Support Bullish View
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Mar 25
539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook
Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.Narrative-Update • Mar 11
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Feb 24
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narrative-Update • Feb 10
539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns
Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Jan 26
539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns
Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative-Update • Jan 10
539871: Stock Split And Bonus Share Flexibility Will Support Future Returns
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).Narrative-Update • Dec 26
539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns
Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).Narrative-Update • Dec 11
539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value
Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.Narrative-Update • Nov 27
539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.Narrative-Update • Nov 12
539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).Narrative-Update • Oct 29
Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).Narrative-Update • Oct 15
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.Narrative-Update • Sep 05
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Neues Narrative • Jan 26
Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader
Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.Aktionärsrenditen
| 539871 | IN Healthcare | IN Markt | |
|---|---|---|---|
| 7D | 2.5% | 2.1% | 2.0% |
| 1Y | 31.3% | 8.0% | 3.6% |
Rendite im Vergleich zur Industrie: 539871 übertraf die Branche Indian Healthcare , die im vergangenen Jahr eine Rendite von 8 erzielte.
Rendite vs. Markt: 539871 übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 3.6 erzielte.
Preisvolatilität
| 539871 volatility | |
|---|---|
| 539871 Average Weekly Movement | 6.0% |
| Healthcare Industry Average Movement | 5.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
Stabiler Aktienkurs: 539871 hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: 539871Die wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 1,906 | Rahul Guha | www.thyrocare.com |
Thyrocare Technologies Limited bietet Patienten, Labors und Krankenhäusern in Indien diagnostische Testdienstleistungen an. Das Unternehmen ist in drei Segmenten tätig: Diagnostische Tests, Imaging Services und Sonstige. Das Unternehmen führt verschiedene medizinische Diagnosetests und Testprofile durch, die sich auf die Früherkennung und das Management von Störungen und Krankheiten konzentrieren, einschließlich Schilddrüse, Wachstum, Stoffwechsel, Autoimmunität, Diabetes, Anämie, Herz-Kreislauf, Unfruchtbarkeit und verschiedene Infektionskrankheiten.
Thyrocare Technologies Limited's Grundlagenzusammenfassung
| 539871 grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹92.18b |
| Gewinn(TTM) | ₹1.76b |
| Umsatz(TTM) | ₹8.76b |
52.3x
Kurs-Gewinn-Verhältnis 10.5x
Kurs-Umsatz-VerhältnisIst 539871 zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| 539871 Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹8.76b |
| Kosten der Einnahmen | ₹3.95b |
| Bruttogewinn | ₹4.82b |
| Sonstige Ausgaben | ₹3.05b |
| Gewinn | ₹1.76b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 11.08 |
| Bruttomarge | 54.96% |
| Nettogewinnspanne | 20.12% |
| Schulden/Eigenkapital-Verhältnis | 8.6% |
Wie hat sich 539871 auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
1.6%
Aktuelle Dividendenrendite91%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/01 09:15 |
| Aktienkurs zum Tagesende | 2026/07/31 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Thyrocare Technologies Limited wird von 13 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | 360 ONE Capital Market Private Limited |
| Hrishikesh Patole | 360 ONE Capital Market Private Limited |
| Rahul Agarwal | CGS International |